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A novel G protein-coupled receptor was cloned by PCR and homology screening. Its deduced amino acid sequence is 47% identical overall to the 
p, 6 and rc opioid receptors and 64% identical in the putative transmembrane domains. When transiently expressed in COS-7 cells this receptor did 
not bind any of the typical p, 6 or K opioid receptor ligands with high affinity. In situ hybridization analysis revealed that LC132 mRNA is highly 
expressed in several rat brain areas, including the cerebral cortex, thalamus, subfornical organ, habenula, hypothalamus, central gray, dorsal raphe, 
locus coeruleus and the dorsal horn of the spinal cord. Based on this distribution and its high homology with the ,u, S and K opioid receptors, it is 
proposed that LC132 is a new member of the opioid receptor family that is involved in analgesia nd the perception of pain. 
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1. Introduction 
The endogenous opioid peptides and the opiate alka- 
loids can affect a wide range of physiological processes 
through interactions with specific receptors. The opioid 
receptors comprise at least three subtypes @, S and rc) 
which are classified on the basis of their pharmacological 
characteristics [1,2]. While screening for novel opioid 
receptors using degenerate oligonucleotides based on the 
mouse &opioid receptor sequence [3,4], we identified a 
clone (LC132) which has high homology at the amino 
acid level but is different from the published ,u, S and FC 
opioid receptors [3-61. Based on the high degree of 
amino acid conservation between LC132 and the p, 6 
and IC opioid receptors in their putative transmembrane 
domains and the cytoplasmic loops we predicted that 
LC132 encodes a G protein-coupled receptor that is a 
previously unrecognized member of the opioid receptor 
family. To test this hypothesis, LC132 cDNA was ex- 
pressed transiently in COS-7 cells for pharmacological 
evaluation, and the distribution of its mRNA in the rat 
central nervous system was mapped by in situ hybridiza- 
tion. 
2. Materials and methods 
First strand cDNA was synthesized from various rat brain regions 
and was used as a template for PCR using the degenerate oligos: 
5’-ATGAATTCAC(GATC)(AG)T(GC)ATGAG(CT)GT(GC)GAC- 
*Corresponding author. Fax: (1) (503) 4944534. 
(CA)G(CA)TA-3’ and 5’-l-IGTCGAC(GA)TA(GA)AG(GA)A(CT)- 
(GATC)GG(GA)TT-3’. The sequences of these oligonucleotides were 
based on putative transmembrane domains (TM) III and VII of the 
mouse bopioid receptor [3,4]. The PCR conditions used were: 94°C 
1 min (denaturation); 50°C for 1.5 min (annealing) and 72’C for 1.5 
min (extension). This cycle was repeated 35 times. PCR products in the 
size range from 400 bp to 750 bp were purified from a 1.0% agarose 
gel using Prep-A-Gene (Bio-Rad), digested with EcoRI and SalI and 
subcloned into the vector pBluescript (Stratagene). The full-length 
mouse S-opioid receptor was recloned from NGl08-15 cDNA by PCR, 
radiolabeled with [a-32P]dCTP by random priming (Prime It; Strat- 
agene) and used to probe nylon membranes (Colony/Plaque Screen; 
NEN) on which recombinant bacteria had been grown. The filters were 
allowed to hybridize with the probe DNA (1 x lo6 cpm/ml) overnight 
in 35% formamide, 5 x SSC, 1% SDS and 5 x Denhardt’s at 37°C with 
slow shaking. They were then washed twice at room temperature in 
2 x SSC, 0.1% SDS followed by several washes at 55’C and exposed 
to Kodak XAR-5 film for 2 days with an intensifying screen at -70°C. 
The inserts of the hybridizing clones were sequenced by the dideoxy 
chain termination method [7]. 
To obtain a full-length clone the LC132 probe was used to screen an 
oligo(dT)-primed rat brain cDNA library in lEGTl1. The hybridization 
conditions used were as described above except hat hybridization was 
in the presence of 50% formamide and the 6nal wash was in 0.5 x SSC, 
0.1% SDS at 55°C. Several positive ;1GTll clones were plaque-purified, 
analyzed by restriction enzyme digestions, subcloned into pBluescript 
and subjected to double-stranded DNA sequencing. 
The 1.3 kb coding region of LC132 was cloned into the eukaryotic 
expression vector RcRSV (Invitrogen). The calcium phosphate precip- 
itation method [8] was used to introduce this construction (LCl32- 
RcRSV) into COS-1 and COS-7 cells. As positive controls for 
expression, cells were transfected in parallel with RcRSV constructs 
containing either rat p [6,9], rat x ([18,19] and our unpublished clone) 
or mouse S [3,4] opioid receptor cDNAs. Stable G418-resistant Ltk- 
and CHO cell lines expressing either LC132 or another opioid receptor 
were also established using the same RcRSV vector (which contains a 
selectable marker for neo?. The stable cell lines that were used in the 
binding studies were selected following Northern blot analysis of 
LC132 mRNA expression. Preparation of the cell membranes and 
protein determinations have been previously described [lo]. Final pro- 
tein concentrations were adjusted to 15-80 mg per binding assay tube. 
The in situ analysis of LC132 mRNA was performed on 30 m thick 
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sections prepared from freshly dissected adult male rat brain and spinal 
cord. An 3SS-labeled antisense riboprobe corresponding to the first 100 
N-terminal amino acids of the receptor was prepared as previously 
described [l 11. This region was chosen because it is poorly conserved 
between LC132 and the p, S and IC opioid receptors. As a negative 
control the complementary sense strand was labeled with [35S]UTP and 
reacted with coronal rat brain sections. The slide-mounted sections 
were first exposed to Cronex film for 5 days, then dipped in emulsion 
and exposed for 2 weeks. 
3. Results and discussion 
Using a strategy that combined PCR, degenerate ol- 
igonucleotide primers based on the mouse bopioid re- 
ceptor [3,4] and low stringency homology screening we 
identified a fragment (spanning a region from putative 
TM111 to TM VII) of a putative G protein-coupled re- 
ceptor the amino acid sequence of which was on average 
67% identical to the rat ,u, the rat FC and the mouse 
S opioid receptors [3-6]. A probe made from this 600 bp 
fragment was then used to isolate LC132, a 3.1 kb 
cDNA, from an oligo(dT)-primed rat brain library. 
When Northern blots of total RNA prepared from rat 
thalamus and rat locus coeruleus were probed with 
LC132, an mRNA of approximately 3.2 kb was detected 
Fig. 1. The cDNA and predicted ammo acid sequence of the LC132 
receptor. The putative transmembrane domains are boxed and num- 
bered with Roman numerals. Triangles indicate potential N-linked 
glycosylation sites and the asterisks indicate potential phosphorylation 
targets of protein kinase C. The nucleotide sequence has been assigned 
GenBank accession umber U01913. 
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(data not shown) suggesting that the cDNA was nearly 
full-length. 
Within the 3.1 kb LC132 cDNA one long open reading 
frame of 367 amino acids was identified (Fig. 1). Hy- 
dropathy analysis of this sequence predicted seven puta- 
tive transmembrane domains, a characteristic feature of 
G protein-coupled receptors. An analysis of LC132’s de- 
duced amino acid sequence revealed three consensus e- 
quences for N-linked glycosylation at its amino-termi- 
nus. As with the ~1, K and 6 opioid receptors, LC132 
contains cysteine residues in the receptor’s putative ex- . 
tracellular loops I and II which may be involved in the 
stabilization of the receptors’ tertiary structure [121. Fur- 
thermore, there are several cysteine residues in LC132’s 
carboxy-terminus that are potential targets of palmitoyl- 
ation [13]. In addition, the receptor encoded by LC132 
also shares with ,u, FC and 6 opioid receptors several con- 
sensus sequences for phosphorylation by protein kinase 
A and protein kinase C, as well as serines and threonines 
that are potential targets of receptor kinases, in the puta- 
tive cytoplasmic loops II and III and the carboxy-termi- 
nus [14,15]. 
The alignment of LC132 with the amino acid se- 
quences of the p, 6 and K opioid receptors revealed that 
145 amino acids, including nine cysteine residues, are 
absolutely conserved among all four receptors (Fig. 2). 
Overall the four receptors are 47% identical, however, 
when only their transmembrane domains are compared 
LC132 is about 64% identical to the rat p, rat FC and 
mouse 6 opioid receptors. Interestingly, when LC132 
was aligned with the published G protein-coupled recep- 
tors, only the somatostatin receptor SSTRl possessed 
significant identity: 32% overall and 51% within the pu- 
tative transmembrane domains [ 163. 
In addition to the high degree of amino acid identity 
in their putative transmembrane domains the LC132, p, 
S and rc receptors also possess extensive conservation in 
their first, second and third putative cytoplasmic loops. 
These domains are critical for productive receptor-G 
protein interactions [171. As a consequence of this exten- 
sive conservation the receptor encoded by LC132 proba- 
bly couples to the same second messenger pathways as 
the other opioid receptors, i.e. inhibition of adenylyl 
cyclase, activation of inward rectifying potassium chan- 
nels and inhibition of N-type calcium channels. When 
taken together, all of the structural information is consis- 
tent with LC132 being a member of the same gene family 
as the p, 6 and FC opioid receptors. 
To pharmacologically characterize the receptor en- 
coded by LC132 its cDNA was cloned into the RcRSV 
expression ,vector. This construction was used to tran- 
siently express the LC132 receptor in COS-1 and COS-7 
cells. In addition this same construction was used to 
stably express the receptor in Ltk- and CHO cells. As 
positive controls for expression rat ,u [6,9], mouse 6 [3,4] 
and K [18,19] opioid receptor cDNAs were cloned into 
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Amino acid alignment 
LC132 MESLFPAPYWEVL 
Rat )kOpioid Receptor MDSSTGPGNTSDCSDPLAQASCSPAPGSWLNLS 
Mouse bopioid Receptor MELVPSARAELQSS 
Mouse I(-Opioid Receptor HESPIQIFRGDPGPTCSPSACLLP 
I 
LC132 YGSHFQGNLSLLNETVPH"LLLNAS"SAFLPLGLK~ji;CII~CL 
p-OR HVDGNQSDPCGLNRTGLGGNDSLCPQTGSPSMVTAITIMALYSIVCVV~~~ 
&-OR PLVNLSDAFPSAFPSAGANASGSPGARSASSLALAIAITALYSAVCAV~~L 
K-OR NSSSWFPNWAESDSNGSVGSEDQQLESAHISPAIPVIITAVYSVVFVV~V~SL 
LC132 VMYVILRH-TNIY In&&I TLVLLT~TDILLGnLCK~ 
JkOR VlflVIvI-TRIYI ~ALATST~SVNYIG~~ILCKIV 
. &OR VWGIVRYTRlXTMHIXI ~LATSTWI~AKY&ME~~L=V 
K-OR VMFVIIRYTKMXTATNIYI- LVTTTMP~AVYLMN -vLQt1v 
III IV 
~~132 ~~~I~I~TSSR~QAV 
,kOR IS-sImT IAVQlsV~FRTPRNAKIVCNWILSEAI 
bOR LSI-#I-T mVPUIIVQlDVRALDFRTPAR1I(LINICI"V&AEGV 
lC-OR ISID-EIITLT MnBvDRYIAvwvKPLKAKII~IcIuLLAasv 
~~132 QVPVAIMGSAQ VEDEEIECLVEIPAP QD~~GPVFA~C*I~~*IOVL~ISV 
- 
&I-OR OLPVMFMATTK YRQGSIDCTLTFSHP TWYWENLLKICV?I~Al'IPILIITV 
&OR OVPIMVMAVTQ PRDFAVVCMLQFPSP SWYUDTVTKI~IZAI'VVPIWIn 
C-OR QISAIVLGGTKVREDVDVIECSLQFPDDEYSW"DLF'MKI~~I?v~~~Iv 
VI 
~~132 CYSIYIRIWGVU~~~~L~~A~~~VQV~LVQGL 
P-OR CYGLM1LX.K SMMWs~LILIUTRMVLVWAVIIV~IHIYVIIKAL 
&OR CYGI,,LLXLRSMLWK~~TRMVL"""~C"~IHIFVIVWTL 
K-OR CYTLMILRLKSVRLWRRDRNUTKLVLWVAv#.IIQTPIHIFILVEAL 
VII 
LC132 GVQPGSETAVAIL RFCTSC I QRKFCCASSLHIU 
P-OR ITIPETTFQTVSW HFCIALUYTZICWIDVL YULDPPIR-FCIPTSSTIZ 
&OR VDINRRDPLVVAALHLCI1L(lrAlsSW -URQLCRTPCGRQlC 
X-OR GSTSHSTAALSSY YFCIALfXTNBSwDVL~ IDIIIIIR~DFCFPIKMI 
LC132 MQVSDRVRSIAKDVGLGCKTSETVPRPA 367 
,,-OR QONSTRVRQNTREHPSTANTVDRTNHQLENLEAETAPLP 398 
&OR PGSLRBPRQATTRERVTACTPSDGPGGGAAA 372 
X-OR RQSTNRVRNTVQDPASMRDVGGMNKPV 380 
Fig. 2. Alignment of the deduced amino acid sequence of the putative 
LC132 receptor with the p, 6 and K opioid receptors. Gaps were intro- 
duced to maximize the alignment. The amino acids that are conserved 
among all four receptors are in boldface print. The putative transmem- 
brane domains are overlined and numbered with Roman numerals. 
Only the complete sequence of LC132 is shown. The numbers at the end 
of the p, 6 and K opioid receptor sequences indicate the number of 
amino acid residues in the respective protein. 
RcRSV and these constructs were both transiently and 
stably expressed in parallel with LC132RcRSV. For the 
binding assays membrane fractions prepared from 
LC132- and the ,u, S and K opioid receptor-expressing 
cells were incubated with a variety of radioligands. In 
spite of repeated efforts none of the membranes prepared 
from any of the LC132-expressing cells (expression was 
evaluated by Northern blotting experiments, data not 
shown) specifically bound [3H]DAMG0, [3H]DPDPE, 
[3H]U-69,593, [3H]diprenorphine, [‘251]B-endorphin, 
[3H]dihydromorphine, [3HJethylketocyclazocine, [3H]- 
dextrorphan or [3H]baclofen. In contrast, when mem- 
branes prepared from cells transfected with either the rat 
p, K or mouse 6 opioid receptors were used in control 
binding experiments they routinely demonstrated robust 
and specific binding of [3H]DAMG0, [3H]U-69,593 and 
[3H]DPDPE, respectively (data not shown). Interest- 
ingly, LC132-expressing membranes did possess low lev- 
els of spectic [3H]naloxone and [3H]bremazocine bind- 
ing. Unfortunately, the level of binding was so low it was 
not possible to pharmacologically characterize LC 132 
using these compounds. When the results of the binding 
studies are considered along with the structural conser- 
vation that LC132 shares with the ,u, 6 and K opioid 
receptors, LC132 appears to be a G protein-coupled re- 
ceptor that is a product of a previously unrecognized 
member of the opioid receptor gene family but with a 
pharmacology that is not that of a classical opioid recep- 
tor. It remains to be determined whether LC132’s en- 
dogenous ligand is one of the many proteolytic frag- 
ments derived from the opioid peptide precursors 
proopiomelanocortin, proenkephalin or prodynorphin, 
or a ligand that remains to be identified. 
In an attempt to identify specific brain regions that 
express LC132 the distribution of its mRNA was deter- 
mined in the central nervous system of the adult male rat 
by in situ hybridization. A freshly dissected rat brain and 
a portion of cervical spinal cord were cut into 30 ,um 
sections and hybridized to an antisense [35S]UTP-ribo- 
probe that corresponded to the first 100 N-terminal 
amino acids of LC132. This region was chosen because 
it is one of the least conserved domains between the 
opioid receptors and LC132. As a negative control sev- 
eral additional sections were hybridized with a sense ri- 
boprobe. To illustrate the distribution of LC132 mRNA 
throughout the central nervous system six coronal sec- 
tions from a complete survey were selected (Fig. 3). In 
the most rostra1 section (Fig. 3A) the paraventricular 
(PVN) and ventral medial hypothalamic nuclei (VMH), 
the periventricular thalamic nucleus (PVA), the 
amygdala (Amg), and the piriform cortex (Pir) are 
densely labeled, while the reticular (Rt) and ventrolateral 
(VL) thalamic nuclei are less so. It is also worth noting 
the diffuse but layered pattern of LC132 labeling in the 
cortex. Of particular interest is the patchy labeling pat- 
tern that is visible in the globus pallidus (GP) compared 
to the lack of label in the caudate pummen (CPU). The 
lack of CPU labeling is in striking contrast to the striatal 
distribution of p, S or K opioid receptor mRNAs (our 
unpublished results). Not shown in this section is the 
intense labeling of the subfornical organ. The patchy 
labeling of the globus pallidus (GP) and the diffuse and 
layered hybridization of LC132 in the cortex continues 
to be visible in the next section (Fig. 3B), while the medial 
habenula (MHb), hippocampus, ventral medial hypo- 
thalamus (VMH), zona incerta (ZI), and the medial nu- 
clei of the amygdala, posterior (Me) and posteroventral 
(MePV) parts are densely labeled. There is a striking lack 
of LC132 hybridization in the ventromedial (VM) and 
mediodorsal (MDC) thalamic nuclei. At the level of the 
midbrain (Fig. 3C) the densest labeling is found in the 
dentate gyrus (DG) as well as CAl, CA2 and CA3 neu- 
rons, however, significant hybridization continues to be 
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evident throughout the cortex, in the periaqueductal 
gray (PAG) and the zona inserta (ZI). Note the absence 
of any signal in the fornix (fx). Fig. 3D is a coronal 
section through the midbrain but caudal to Fig. 3B and 
illustrates the dense labeling of the dorsal raphe (DR), 
pontine gray (PG), and the superior colliculus (SC). Ad- 
ditional hybridization appears as a diffuse signal in the 
periaqueductal gray (PAG) and the pontine reticular nu- 
cleus (PRNT). The intense labeling of the locus coeruleus 
(LC) is the predominant signal in the pons (Fig. 3E), 
281 
however, the nucleus raphe magnus (RM), pontine cen- 
tral gray (PCG), olivary nuclei (ON) and the anterior 
aspect of the ventral cochlear nucleus (VCOa) are, all be 
it diffusely, labeled significantly. At the level of the cervi- 
cal spinal cord a characteristic patchy signal arranged in 
an H-shaped pattern is seen in both the anterior (AGH) 
and posterior (PGH) gray horns (Fig. 3F). Note the 
absence of staining in the lateral (LF) and anterior fu- 
niculi (AF). The sections incubated with the sense LC132 
riboprobe failed to hybridize to the probe (data not 
Fig. 3. Distribution of LC132 mRNA in the rat central nervous system and cervical spinal cord. The most rostral coronal section (A) is through 
the diencephalon. The paraventricular (PVN) and ventral medial hypothalamic nuclei (VMH); the periventricular thalamic nucleus (PVA); the 
amygdala (Amg); and the piriform cortex (Pir) are densely labeled while the reticular (Rt) and ventrolateral (_I%) thalamic nuclei are less so. The 
cortex is also significantly labeled in a diffuse but layered pattern. Of particular interest is the patchy labeling pattern in the globus palhdus (GP) 
as compared to the lack of label in the caudate putamen (CPU). The patchy globus pallidus (GP) labeling and the diffuse and layered hybridization 
of LC132 in the cortex continues to be visible in (R) while the medial habenula (MHb), hippocampus, ventral medial hypothalamus (VMH), zona 
incerta (ZI), and the medial nuclei of the amygdala, posterior (Me) and posteroventral (MePV) parts are densely labeled. There is a striking lack 
of LC132 hybridization in the ventromedial (VM) and mediodorsal (MDC) thalamic nuclei. At the level of the midbrain (C) the densest labeling is 
found in the dentate gyrus (DG) as well as CAl, CA2 and CA3 neurons while sign&ant hybridization continues to be evident hroughout he cortex, 
in the periaqueductal gray (PAG) and the zona mserta (ZI). Note the absence of any signal in the fornix (fx). (D) A more caudal coronal section 
through the midbrain in which dense labeling of the dorsal raphe (DR), pontine gray (PG), and the superior colliculus (SC) is seen. Additional 
hybridization appears as a ditTuse signal in the periaqueductal gray (PAG) and the pontine reticular nucleus (PRNT). The intense labeling of the 
locus coeruleus (LC) is the predominant signal in the pons Q, however, the nucleus raphe magnus (RM), pontine central gray (PCG), olivary nuclei 
(ON) and the anterior aspect of the ventral cochlear nucleus (VCOa) are also signiiicantly labeled. At the level of the cervical spinal cord (F) a 
characteristic patchy signal arranged in an H-shaped pattern is seen in both the anterior (AGH) and posterior (PGH) gray horns. There is no LC132 
reactive sequence in the lateral (LP) and anterior funiculi (AF). 
288 
shown), consistent with our interpretation that the signal 
we detected with the antisense probe was specific. 
In summary we have cloned a novel rat G protein- 
coupled receptor that shares extensive amino acid se- 
quence identity with the 6, K and p opioid receptor types. 
Although a labeled ligand has not been identified the 
dense expression of LC132 mRNA in limbic, cortical and 
spinal cord nuclei is consistent with an abundant recep- 
tor that mediates analgesia and the perception of pain. 
When the identification of its endogenous ligand has 
been accomplished the role of this previously unknown, 
yet abundant, member of the opioid receptor gene family 
will become clearer. 
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Note added in proof 
During the preparation and review of this manuscript Mollereau et al. [20] reported the cloning of a human receptor 
that is 92% identical to LC132 and Fukuda et al. [21] reported a rat amino acid sequence that is identical to LC132. 
